Close



Apr 6, 2022 09:02AM
Aug 10, 2021 09:25AM
Jul 6, 2019 05:19AM
Jun 25, 2019 08:00AM
May 29, 2019 11:56AM
May 29, 2019 11:55AM
May 21, 2019 08:01AM Array Biopharma (ARRY) Announces BRAFTOVI + MEKTOVI + Cetuximab Meet Primary Endpoints of ORR and OS in Phase 3 BEACON CRC Trial
May 21, 2019 08:00AM
May 7, 2019 08:00AM
Mar 18, 2019 08:07AM
Mar 18, 2019 08:00AM
Feb 5, 2019 08:00AM
Jan 14, 2019 05:05PM
Jan 14, 2019 05:03PM Array BioPharma Announces 15.3 Months Median Overall Survival from the Safety Lead-in of the Phase 3 BEACON CRC Trial of the Combination BRAFTOVI®, MEKTOVI® and ERBITUX® in BRAF-Mutant Metastatic C
Oct 30, 2018 08:00AM
Sep 20, 2018 02:04PM
Sep 20, 2018 02:02PM
Sep 13, 2018 08:07AM
Sep 13, 2018 08:00AM
Aug 14, 2018 08:01AM
Aug 14, 2018 08:00AM Array BioPharma Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2018
Aug 10, 2018 08:01AM
Aug 10, 2018 08:00AM
Aug 7, 2018 08:11AM
Aug 7, 2018 08:00AM
Jul 27, 2018 08:37AM
Jul 27, 2018 08:30AM
Jul 13, 2018 08:10AM Array Biopharma (ARRY) Reports Updated Clinical Practice Guidelines from NCCN for BRAFTOVI (encorafenib) in Combination with MEKTOVI (binimetinib) as Category 1 Treatment Option
Jul 13, 2018 08:00AM
Jun 28, 2018 08:12AM
Jun 27, 2018 01:48PM
Jun 27, 2018 01:44PM
Jun 27, 2018 12:53PM
Jun 25, 2018 05:52AM
Jun 23, 2018 07:00AM Array BioPharma Announces a 62% Observed Overall Survival at One Year from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant CRC at the
Jun 18, 2018 08:04AM
Jun 18, 2018 08:00AM
Jun 4, 2018 08:01AM
Jun 4, 2018 08:00AM
May 9, 2018 08:00AM
Mar 22, 2018 09:06AM
Mar 22, 2018 09:00AM Array BioPharma Announces Publication of Detailed Phase 3 COLUMBUS Trial Data of Encorafenib and Binimetinib in Melanoma Patients in The Lancet Oncology
Feb 7, 2018 11:27AM
Feb 6, 2018 08:05AM
Feb 6, 2018 08:03AM
Feb 6, 2018 08:00AM
Jan 22, 2018 05:45AM
Jan 20, 2018 10:05AM
Jan 16, 2018 08:00AM Array BioPharma to Present Updated Phase 3 BEACON CRC Safety Lead-In Results of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant Colorectal Cancer at the 2018 Gastrointestinal
Dec 22, 2017 07:49AM

251,865 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All